BRITANNIA GATEWAY BUSINESS PARK LEASELease • August 10th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BRITANNIA GATEWAY II LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and AUDENTES THERAPEUTICS, INC., a Delaware corporation ("Tenant").
THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTAudentes Therapeutics, Inc. • August 10th, 2017 • Biological products, (no disgnostic substances)
This THIRD AMENDMENT (“Third Amendment”) is entered into as of July 14, 2017 (the “Third Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Audentes”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Audentes and Penn are referred to collectively as the “Parties” and individually as a “Party.”
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 10th, 2017 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated License Agreement (“Agreement”) is effective as of September 26, 2014 (the “Effective Date”) by and between Istituti Clinici Scientifici Maugeri S.p.A. SB (assignee of Fondazione Salvatore Maugeri, "FSM"), an organization established under the laws of Italy (“Maugeri”), and Audentes Therapeutics, Inc., a Delaware corporation (“Audentes”), and amends and restates in its entirety that certain License Agreement dated as of the Effective Date by and between Cardiogen Sciences, Inc. (“Cardiogen”) and FSM (the “Original Agreement”). Each of Maugeri and Audentes are referred to herein as “Party” and together as the “Parties.”
